Trial Profile
A Phase 1, Randomized, Single Blind, Placebo Controlled, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN PCSSC in Subjects With Elevated Low Density Lipoprotein Cholesterol
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Inclisiran (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions
- Sponsors Alnylam Pharmaceuticals
- 16 Nov 2016 Results (n=51) presented at the 89th Annual Scientific Sessions of the American Heart Association
- 13 Nov 2016 Results assessing safety published in the New England Journal of Medicine (2016).
- 13 Nov 2016 Results published in Alnylam Pharmaceuticals media release.